<DOC>
	<DOCNO>NCT01124604</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety explore pharmacokinetics ( drug absorb body , distribute within body remove body time ) tapentadol hydrochloride extend release ( ER ) tablets Japanese participant moderate severe chronic pain due osteoarthritis ( disorder joint become painful stiff ) knee low back pain .</brief_summary>
	<brief_title>An Efficacy Safety Study Tapentadol Extended Release ( JNS024ER ) Chronic Pain Participants</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , multi-center ( one hospital medical school team work medical research study ) , double-blind ( neither physician participant know name assigned drug ) , placebo-control ( participant randomly assign test treatment identical-appearing treatment contain test drug ) , parallel-group ( group participant treat time ) comparison study participant chronic pain due osteoarthritis knee low back pain . The study duration 14 week , consist screen period 1 week participant evaluate study eligibility , treatment period 12 week follow-up period 1 week . The treatment period consist titration period ( initiation study treatment determination individual 's maintenance dose ) maintenance period ( completion titration period completion treatment period ) . An optimal dose ( maintenance dose ) determine participant titration period treatment continue maintenance dose ass efficacy safety . Tapentadol hydrochloride ER tablets 25 250 milligram placebo administer orally twice daily . Efficacy safety participant primarily evaluate change baseline average pain intensity score base 11-point Numerical Rating Scale ( NRS ) Clinical Opiate Withdrawal Scale ( COWS ) , respectively . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Participants chronic pain due osteoarthritis knee low back pain continue least 12 week inform consent Participants achieve adequate analgesia ( pain control ) routine treatment oral nonopioid analgesic ( drug use control pain ) usual upperlimit dose adequate fix dose least 14 consecutive day 12 week inform consent Participants experience treatment conventional opioids , except short term use opioid analgesic treatment postoperative acute pain 30 day consent temporary use codeine phosphate dihydrocodeine phosphate purpose pain relief ( e.g . antitussive ) 2 day inform consent Participants average pain intensity score great equal 5 11point Numerical Rating Scale ( NRS ) 48 hour inform consent consider require opioid treatment Investigator Participants able visit medical institution throughout study period Participants take monoamine oxidase inhibitor within 14 day inform consent Participants current history epilepsy seizure disorder Participants suspect intracranial hypertension ( e.g . traumatic encephalopathy ) Participants uncontrolled clinically significant arrhythmia ( irregular heart rate ) Participants moderate severe liver dysfunction severe renal dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Pain</keyword>
	<keyword>Low Back Pain</keyword>
	<keyword>Back Pain</keyword>
	<keyword>Osteoarthritis , Knee</keyword>
	<keyword>Tapentadol</keyword>
	<keyword>Tapentadol Hydrochloride Extended Release</keyword>
</DOC>